Summit Therapeutics plc
('Summit' or the "'Company')
Result of Annual General Meeting
Oxford, UK, and Cambridge, MA, US, 7 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that all resolutions proposed to shareholders at the Company's Annual General Meeting ('AGM') held earlier today have been passed. The results of the proxy votes lodged in advance and at the meeting will be available shortly from the Investors section of Summit's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications in neuromuscular and infectious diseases for which there are no existing or only inadequate therapies. Summit is currently conducting clinical programmes focused on the neuromuscular disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
Contacts
Summit | ||
Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson | ||
N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer | ||
Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
Freddy Crossley, Corporate Finance | ||
MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
Karen Sharma | ksharma@macbiocom.com | |
Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
Mary-Jane Elliott / Jessica Hodgson / | summit@consilium-comms.com | |
Lindsey Neville / Philippa Gardner |
-END-